Shots:
- The EC has approved Amvuttra (vutrisiran) to treat ATTR-CM adults as an additional indication, based on the global P-III (HELIOS-B) study assessing it vs PBO in ATTR-CM pts
- The study met all ten 1 & 2EPs across both overall & monotx. arms, showing improved outcomes of mortality, CV events & functional capacity with 6min. walk test
- The trial also showed benefits across health status, QoL (Kansas City Cardiomyopathy Questionnaire), plus heart failure symptoms & severity (NYHA class). In the overall population, the primary composite endpoint was reduced by 28%, and mortality was reduced by 36% over 42mos. Data was published in The NEJM
Ref: Businesswire | Image: Alnylam Pharmaceuticals| Press Release
Related News:- Arvinas and Pfizer Report the US FDA’s NDA Submission of Vepdegestrant for ESR1-Mutated Breast Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
